FDA warned compounding pharmacy Pharmacy Innovations that its sterile drugs were made under insanitary conditions and without valid patient prescriptions.
What happened
FDA investigators inspected the firm's Erie, Pennsylvania facility from November 2 to November 30, 2022. They found visibly dirty, porous and rusting surfaces in the sterile processing areas, microbial contamination that the firm detected but did not properly correct, poor aseptic technique by operators, and air systems that could let lesser-quality air reach sterile work areas. Investigators also found the firm made some drugs, including Lidocaine/Tetracaine/Phenylephrine 20/4/2% Gel and Dutasteride 0.1% injectable, without valid prescriptions for individually identified patients. The firm recalled all sterile compounded products made between October 2 and November 30, 2022, and stopped sterile production in the affected hood.
What FDA found
Sterile drugs were prepared in areas with rust, holes in walls, dust and trash, so they may have been contaminated.
Section 501(a)(2)(A) of the FDCA [21 U.S.C. § 351(a)(2)(A)]The firm found microbial contamination in its sterile processing area in 2020 and again in 2022 but did not properly fix the cause.
Section 501(a)(2)(A) of the FDCA [21 U.S.C. § 351(a)(2)(A)]Air of lower quality could enter the sterile hood and cleanroom, HEPA filters leaked, air speed was low and airflow was turbulent.
Section 501(a)(2)(A) of the FDCA [21 U.S.C. § 351(a)(2)(A)]Operators touched sterile surfaces with gloved hands, blocked first air, moved too fast and let trash build up on the air intake grille.
Section 501(a)(2)(A) of the FDCA [21 U.S.C. § 351(a)(2)(A)]Media fills, the tests used to show a sterile process works, were not run under the hardest conditions the firm actually uses.
Section 501(a)(2)(A) of the FDCA [21 U.S.C. § 351(a)(2)(A)]Some drugs were compounded without valid prescriptions for identified patients, so they lost the 503A exemption and were unapproved new drugs with labeling lacking adequate directions for use.
Section 503A [21 U.S.C. § 353a]; sections 505(a) and 301(d) [21 U.S.C. §§ 355(a), 331(d)]; section 502(f)(1) [21 U.S.C. § 352(f)(1)]
What FDA wants
Within 15 working days, the firm must write to FDA describing the specific steps taken to fix the violations, or state that it will not resume sterile production. If it plans to resume sterile production, it must also explain how it will prevent recurrence, send supporting documentation, and notify FDA 15 working days before restarting.
Who should pay attention
- home infusion and health system pharmacies that buy compounded sterile drugs
- patients and clinicians receiving compounded sterile injectables or ophthalmic products
- compounding pharmacies that rely on the 503A exemption
This is a summary. Read the original letter on fda.gov.